SBIR/STTR Research Award
XRpro Radioactive Cesium Decorporation Agents
Award amount
$600,000Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Icagen, Inc.
- Proposal award date
- 2014-07-01
- Contract end date
- 2017-06-30
- UEI
- Not reported
- Solicitation number
- PA12-044
- Topic code
- NIAID
Research abstract
DESCRIPTION provided by applicant Caldera aims to develop an inexpensive stable selective decorporation decorp agent for cesium Cs Cs is easily obtainable by terrorists and treatments for exposures are Project Bioshield priorities for use in radiation nuclear emergencies high priority for DHHS NIH NIAID DAIT and a critical need for the Strategic National Stockpile SNS Calderaandapos s agent will select for Cs over potassium K sodium Na and other elements that are essential for human health Current treatments are non selective and must be used under strict clinical supervision Selectivity is needed because Na and K are more prevalent than Cs in the body non selective decorp agents are swamped by Na and K Na K and Cs have similar properties so selective treatments are traditionally very difficult to develop Agents such as Prussian Blue PB are current treatments for Cs exposure however PB only binds Cs from the gastrointestinal tract GI DTPA analogs have been approved by the FDA for treatment of plutonium americium and curium but they are in intravenous forms so are difficult to administer in response to mass exposure Calderaandapos s approach focuses on chelating radioactive Cs in blood and muscle that has been absorbed systemically from all exposure routes oral dermal inhaled There are no decorp agents to selectively remove Cs from the bloodstream and musculature Caldera will use XRpro r a high throughput screening HTS label free x ray fluorescence XRF technology to produce selective decorp agents for Cs and other radioisotopes XRpro r protocols instruments microarrays and novel ligands increase the signal and decrease the noise for measuring Cs increasing the likelihood that Phase I will result in novel selective Cs decorp agents PUBLIC HEALTH RELEVANCE Caldera aims to develop an inexpensive stable selective decorporation decorp agent for cesium Cs Cs is easily obtainable by terrorists and treatments for exposures are Project Bioshield priorities for use in radiation nuclear emergencies high priority for DHHS NIH NIAID DAIT and a critical need for the Strategic National Stockpile SNS Calderaandapos s agent will select for Cs over potassium K sod ium Na and other elements that are essential for human health Current treatments are non selective and must be used under strict clinical supervision
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients